The third Scientific Meeting of 2024 was held in August. Three concepts were presented that each encompassed multidisciplinary approaches to improving thoracic cancer outcomes, including SCLC, early-stage detection of lung cancers, and NSCLC-SCLC transformation. All three concepts were unanimously endorsed by the Scientific Committee.
Key Highlights 2025 to-date
- 12 concepts were submitted – 10 concepts have reviewed by the most relevant working group/s and the remaining 2 will be reviewed in the next peer-review round.
- 6 clinical studies were recommended to the Scientific Committee and the remaining 4 concepts were surveys and approved to be distributed to TOGA’s membership.
- The Scientific Committee has endorsed all 6 clinical studies for further development and TOGA support.
– Five of these concepts require funding and have been submitted or intend to submit for grant funding.
– The reminding one aims to deliver an international clinical trial to Australia that already has funding and will bring access to a new therapeutic currently not reimbursed in Australia.
– Four of the supported clinical studies will leverage previously endorsed studies and platforms, including ASPiRATION-2L and the TRACKER biobank.
Acknowledgments
We thank all those who submitted concepts, and all TOGA members who have joined the Scientific Committee and the working groups to review the submissions. Peer and consumer-review is a critical component of TOGA’s research program to ensure high-quality, feasible, and relevant research in thoracic cancers.
Additional Information
If you have any questions about the Scientific Meeting or any of the concepts that were presented, please contact the TOGA office at info@thoraciconcology.org.au
